WHO ICTRP trial
Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for…
JPRN-UMIN000015175 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000015175 |
|---|---|
| Public title | Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial. |
| Scientific title | Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial. - STAR study |
| Primary sponsor | St.Marianna University School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Rheumatoid Arthritis |
| Interventions | Subcutaneous Tocilizumab 162mg every other week. Subcutaneous Abatacept 125mg every week. |
| Registration date | Sep 17, 2014 |
| Target size | 120 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: